|
| DRUG REVIEW |
|
| Year : 2010 | Volume
: 56
| Issue : 2 | Page : 163-167 |
Posaconazole
M Bhattacharya1, K Rajeshwari1, B Dhingra2
1 Department of Pediatrics, Maulana Azad Medical College & Lok Nayak Hospital, New Delhi, India
2 Department of Hematology & Oncology, All India Institute of Medical Sciences, Delhi, India
Correspondence Address:
M Bhattacharya
Department of Pediatrics, Maulana Azad Medical College & Lok Nayak Hospital, New Delhi
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0022-3859.65281
Posaconazole is a novel second-generation Triazole oral antifungal agent. It is highly effective in the prophylaxis of invasive fungal infections in immunocompromised patients. It is used as a first-line agent as well as for salvage therapy in invasive fungal infections including aspergillosis, oropharyngeal and esophageal candidiasis. It has a good adverse effect profile. With the rising incidence of invasive fungal infections due to the HIV pandemic and medical advancements in transplantation and cancer therapy, these features make posaconazole a valuable addition in the family of antifungal agents.
[FULL TEXT] [PDF]*
|
